Review





Similar Products

96
ATCC human embryonic kidney hek293 cells
MiR-136-3p content in cell culture medium and uptake of extracellular miR-136-3p into cultured myotubes. MiRNA content in (A) human myotubes and (B) human pancreatic islets culture media. Results were first normalized using RNU1A1 and then presented in relation to miR-23a-3p content for n = 4 different donors for myotubes cultures and n = 4 donors for human islets. Left panel (C) shows bright-field image of cultured human myotubes and right panel (C) shows a representative fluorescence image of cultured human myotubes with cells exposed to human serum-derived EVs loaded with Cy3-miR-136-3p. Cy3 fluorescence (red) is detected in the whole cytoplasm of the human myotubes. (D) Representative fluorescence image of human myotubes exposed to <t>HEK293</t> culture medium with EVs loaded with Cy3-miR-136-3p (red). (E) Representative image of human myotubes exposed to EVs loaded with TexasRed-labeled with a control RNA (orange). Nuclear Hoechst staining is shown in blue. Scale bar = 100 μm. EVs = extracellular vesicles; HEK293 = <t>human</t> <t>embryonic</t> <t>kidney;</t> miR = microRNA; Rel = relative; RNU1A1 = U1 small nuclear RNA.
Human Embryonic Kidney Hek293 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/Human+embryonic+kidney+cells%2C+293-hY2-10/pmc12811471-83-0-8
Average 96 stars, based on 1 article reviews
human embryonic kidney hek293 cells - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney 293 t cells
MiR-136-3p content in cell culture medium and uptake of extracellular miR-136-3p into cultured myotubes. MiRNA content in (A) human myotubes and (B) human pancreatic islets culture media. Results were first normalized using RNU1A1 and then presented in relation to miR-23a-3p content for n = 4 different donors for myotubes cultures and n = 4 donors for human islets. Left panel (C) shows bright-field image of cultured human myotubes and right panel (C) shows a representative fluorescence image of cultured human myotubes with cells exposed to human serum-derived EVs loaded with Cy3-miR-136-3p. Cy3 fluorescence (red) is detected in the whole cytoplasm of the human myotubes. (D) Representative fluorescence image of human myotubes exposed to <t>HEK293</t> culture medium with EVs loaded with Cy3-miR-136-3p (red). (E) Representative image of human myotubes exposed to EVs loaded with TexasRed-labeled with a control RNA (orange). Nuclear Hoechst staining is shown in blue. Scale bar = 100 μm. EVs = extracellular vesicles; HEK293 = <t>human</t> <t>embryonic</t> <t>kidney;</t> miR = microRNA; Rel = relative; RNU1A1 = U1 small nuclear RNA.
Human Embryonic Kidney 293 T Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/293T/pmc13753392-41-0-12
Average 99 stars, based on 1 article reviews
human embryonic kidney 293 t cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney 293t hek 293t cells

Human Embryonic Kidney 293t Hek 293t Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/293T/pmc13760956-20-0-8
Average 99 stars, based on 1 article reviews
human embryonic kidney 293t hek 293t cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney cells hek293t
LFA‐1 engineering enhances EV localization to ECs. (A) Schematic illustration of the generation of LFA‐1‐engineered EVs. <t>HEK293T</t> cells were transfected with plasmids encoding CD11a and CD18, or vector control plasmids. EV Con and EV LFA‑1 were subsequently isolated from conditioned media by ultracentrifugation. (B) Western blot analysis using 50 µg EV protein lysates, showing expression of CD11a, CD18, and EV markers. (C and D) WT mice ( n = 4 per group) were treated intratracheally with LPS (5 µg per mouse). After 24 h, mice received an intravenous injection of 200 µg PKH26‑labeled EV Con or EV LFA‑1 and were euthanized 24 h later. Lung sections were stained with antibodies against CD68 (C) or CD31 (D). Nuclei were counterstained with DAPI. Scale bar = 50 µm. All in vitro experiments were conducted in three independent biological replicates.
Human Embryonic Kidney Cells Hek293t, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/293T%2F17/pmc13752224-76-0-8
Average 99 stars, based on 1 article reviews
human embryonic kidney cells hek293t - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney cells
LFA‐1 engineering enhances EV localization to ECs. (A) Schematic illustration of the generation of LFA‐1‐engineered EVs. <t>HEK293T</t> cells were transfected with plasmids encoding CD11a and CD18, or vector control plasmids. EV Con and EV LFA‑1 were subsequently isolated from conditioned media by ultracentrifugation. (B) Western blot analysis using 50 µg EV protein lysates, showing expression of CD11a, CD18, and EV markers. (C and D) WT mice ( n = 4 per group) were treated intratracheally with LPS (5 µg per mouse). After 24 h, mice received an intravenous injection of 200 µg PKH26‑labeled EV Con or EV LFA‑1 and were euthanized 24 h later. Lung sections were stained with antibodies against CD68 (C) or CD31 (D). Nuclei were counterstained with DAPI. Scale bar = 50 µm. All in vitro experiments were conducted in three independent biological replicates.
Human Embryonic Kidney Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/293/pmc13753295-25-0-10
Average 99 stars, based on 1 article reviews
human embryonic kidney cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

98
DSMZ human embryonic kidney cells
LFA‐1 engineering enhances EV localization to ECs. (A) Schematic illustration of the generation of LFA‐1‐engineered EVs. <t>HEK293T</t> cells were transfected with plasmids encoding CD11a and CD18, or vector control plasmids. EV Con and EV LFA‑1 were subsequently isolated from conditioned media by ultracentrifugation. (B) Western blot analysis using 50 µg EV protein lysates, showing expression of CD11a, CD18, and EV markers. (C and D) WT mice ( n = 4 per group) were treated intratracheally with LPS (5 µg per mouse). After 24 h, mice received an intravenous injection of 200 µg PKH26‑labeled EV Con or EV LFA‑1 and were euthanized 24 h later. Lung sections were stained with antibodies against CD68 (C) or CD31 (D). Nuclei were counterstained with DAPI. Scale bar = 50 µm. All in vitro experiments were conducted in three independent biological replicates.
Human Embryonic Kidney Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/293T/pmc13748912-311-0-5
Average 98 stars, based on 1 article reviews
human embryonic kidney cells - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney 293t cells
LFA‐1 engineering enhances EV localization to ECs. (A) Schematic illustration of the generation of LFA‐1‐engineered EVs. <t>HEK293T</t> cells were transfected with plasmids encoding CD11a and CD18, or vector control plasmids. EV Con and EV LFA‑1 were subsequently isolated from conditioned media by ultracentrifugation. (B) Western blot analysis using 50 µg EV protein lysates, showing expression of CD11a, CD18, and EV markers. (C and D) WT mice ( n = 4 per group) were treated intratracheally with LPS (5 µg per mouse). After 24 h, mice received an intravenous injection of 200 µg PKH26‑labeled EV Con or EV LFA‑1 and were euthanized 24 h later. Lung sections were stained with antibodies against CD68 (C) or CD31 (D). Nuclei were counterstained with DAPI. Scale bar = 50 µm. All in vitro experiments were conducted in three independent biological replicates.
Human Embryonic Kidney 293t Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/293T/pmc13762209-78-0-15
Average 99 stars, based on 1 article reviews
human embryonic kidney 293t cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney 293 cells
LFA‐1 engineering enhances EV localization to ECs. (A) Schematic illustration of the generation of LFA‐1‐engineered EVs. <t>HEK293T</t> cells were transfected with plasmids encoding CD11a and CD18, or vector control plasmids. EV Con and EV LFA‑1 were subsequently isolated from conditioned media by ultracentrifugation. (B) Western blot analysis using 50 µg EV protein lysates, showing expression of CD11a, CD18, and EV markers. (C and D) WT mice ( n = 4 per group) were treated intratracheally with LPS (5 µg per mouse). After 24 h, mice received an intravenous injection of 200 µg PKH26‑labeled EV Con or EV LFA‑1 and were euthanized 24 h later. Lung sections were stained with antibodies against CD68 (C) or CD31 (D). Nuclei were counterstained with DAPI. Scale bar = 50 µm. All in vitro experiments were conducted in three independent biological replicates.
Human Embryonic Kidney 293 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/293/pmc13762018-69-0-6
Average 99 stars, based on 1 article reviews
human embryonic kidney 293 cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney cell t hek293t
A) Schematic of the CRISPR screen workflow. B-C) Volcano plots of (B) the kinome screen results showing the log 2 FC vs −log 10 p-adjusted value (FDR<0.05) enrichment score per gene or (C) the genome-wide screen results showing the log 2 FC vs −log 10 p-value (p<0.08) enrichment score per gene that increased MeCP2 (green) or decreased MeCP2 (red) expression. D-E) Validation of top screen hits on endogenous MeCP2 levels relative to loading control (GAPDH) in <t>HEK293T</t> cells using independent sgRNAs or dual guide RNA vectors (dgRNAs). Combined bar plot showing target gene knockout (KO) efficiency (left) and corresponding changes to MeCP2 levels (right) as measured by western blot quantification compared to respective non-targeting (NT) control samples, stabilizers (red) and destabilizers (green). Data presented as mean ± SEM, **p<0.005, ***p<0.0005, ****p<0.0001 using a one-way ANOVA with post-hoc Dunnett’s multiple comparisons between gene-targeting sgRNAs or dgRNAs to respective NT samples. F-I) Quantification of endogenous MeCP2 levels relative to loading controls (GAPDH or VCL) in HEK293T cells after 72hr incubation with (F) BRD4 inhibitor JQ1 at 10uM, (G) CDK9 inhibitor LDC000067 at 10uM, (H) MTOR inhibitor Rapamycin at 1 uM, or (I) agonist of AMPK pathway Metformin at 0.5uM. Data presented as mean ± SEM, p-values determined using a Student’s t-test.
Human Embryonic Kidney Cell T Hek293t, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+kidney/293T/bio_rxiv__64898__2026__11__05__764603-182-0-9
Average 99 stars, based on 1 article reviews
human embryonic kidney cell t hek293t - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


MiR-136-3p content in cell culture medium and uptake of extracellular miR-136-3p into cultured myotubes. MiRNA content in (A) human myotubes and (B) human pancreatic islets culture media. Results were first normalized using RNU1A1 and then presented in relation to miR-23a-3p content for n = 4 different donors for myotubes cultures and n = 4 donors for human islets. Left panel (C) shows bright-field image of cultured human myotubes and right panel (C) shows a representative fluorescence image of cultured human myotubes with cells exposed to human serum-derived EVs loaded with Cy3-miR-136-3p. Cy3 fluorescence (red) is detected in the whole cytoplasm of the human myotubes. (D) Representative fluorescence image of human myotubes exposed to HEK293 culture medium with EVs loaded with Cy3-miR-136-3p (red). (E) Representative image of human myotubes exposed to EVs loaded with TexasRed-labeled with a control RNA (orange). Nuclear Hoechst staining is shown in blue. Scale bar = 100 μm. EVs = extracellular vesicles; HEK293 = human embryonic kidney; miR = microRNA; Rel = relative; RNU1A1 = U1 small nuclear RNA.

Journal: Journal of Sport and Health Science

Article Title: Exercise training-induced extracellular miR-136-3p modulates glucose uptake and myogenesis through targeting of NRDC in human skeletal muscle

doi: 10.1016/j.jshs.2025.101091

Figure Lengend Snippet: MiR-136-3p content in cell culture medium and uptake of extracellular miR-136-3p into cultured myotubes. MiRNA content in (A) human myotubes and (B) human pancreatic islets culture media. Results were first normalized using RNU1A1 and then presented in relation to miR-23a-3p content for n = 4 different donors for myotubes cultures and n = 4 donors for human islets. Left panel (C) shows bright-field image of cultured human myotubes and right panel (C) shows a representative fluorescence image of cultured human myotubes with cells exposed to human serum-derived EVs loaded with Cy3-miR-136-3p. Cy3 fluorescence (red) is detected in the whole cytoplasm of the human myotubes. (D) Representative fluorescence image of human myotubes exposed to HEK293 culture medium with EVs loaded with Cy3-miR-136-3p (red). (E) Representative image of human myotubes exposed to EVs loaded with TexasRed-labeled with a control RNA (orange). Nuclear Hoechst staining is shown in blue. Scale bar = 100 μm. EVs = extracellular vesicles; HEK293 = human embryonic kidney; miR = microRNA; Rel = relative; RNU1A1 = U1 small nuclear RNA.

Article Snippet: Human embryonic kidney (HEK293) cells were obtained from American Type Culture Collection (ATCC) and cultured in high-glucose (4.5 g/L) Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% (vol/vol) FBS.

Techniques: Cell Culture, Fluorescence, Derivative Assay, Labeling, Control, Staining

NRDC is a direct target of miR-136-3p in human myotubes. Skeletal muscle NRDC mRNA is responsive to training and inactivity. (A) Tissue mRNA expression of NRDC from the Human Protein Atlas database showing enriched expression of NRDC in human skeletal muscle. (B) The miR-136-3p target site in the NRDC gene is highly conserved in mammals. (C) Luciferase activity in HEK293 cells co-transfected the NRDC 3’UTR and miR-136-3p with or without anti-miR136-3p inhibitors. miR-136-3p transfection downregulates NRDC (D) mRNA and (E) representative image of protein abundance in human myotubes. (F) Publicly available data ( GSE14413 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 6 weeks of endurance training ( n = 8). (G) Publicly available data ( GSE120862 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 2 months of aerobic training ( n = 10). (H) Publicly available data ( GSE14901 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 14 days of immobilization ( n = 24). * p < 0.05, ** p < 0.005. GSE = gene set enrichment; HEK293 = human embryonic kidney; miR = microRNA; NC = negative control; NRDC = nardilysin convertase; nTPM = normalized transcripts per million; si NRDC = small interfering RNA of NRDC ; UTR = untranslated region.

Journal: Journal of Sport and Health Science

Article Title: Exercise training-induced extracellular miR-136-3p modulates glucose uptake and myogenesis through targeting of NRDC in human skeletal muscle

doi: 10.1016/j.jshs.2025.101091

Figure Lengend Snippet: NRDC is a direct target of miR-136-3p in human myotubes. Skeletal muscle NRDC mRNA is responsive to training and inactivity. (A) Tissue mRNA expression of NRDC from the Human Protein Atlas database showing enriched expression of NRDC in human skeletal muscle. (B) The miR-136-3p target site in the NRDC gene is highly conserved in mammals. (C) Luciferase activity in HEK293 cells co-transfected the NRDC 3’UTR and miR-136-3p with or without anti-miR136-3p inhibitors. miR-136-3p transfection downregulates NRDC (D) mRNA and (E) representative image of protein abundance in human myotubes. (F) Publicly available data ( GSE14413 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 6 weeks of endurance training ( n = 8). (G) Publicly available data ( GSE120862 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 2 months of aerobic training ( n = 10). (H) Publicly available data ( GSE14901 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 14 days of immobilization ( n = 24). * p < 0.05, ** p < 0.005. GSE = gene set enrichment; HEK293 = human embryonic kidney; miR = microRNA; NC = negative control; NRDC = nardilysin convertase; nTPM = normalized transcripts per million; si NRDC = small interfering RNA of NRDC ; UTR = untranslated region.

Article Snippet: Human embryonic kidney (HEK293) cells were obtained from American Type Culture Collection (ATCC) and cultured in high-glucose (4.5 g/L) Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% (vol/vol) FBS.

Techniques: Expressing, Luciferase, Activity Assay, Transfection, Quantitative Proteomics, Negative Control, Small Interfering RNA

Journal: STAR Protocols

Article Title: Protocol for the production of high-yielded research-grade AAV vectors in transiently transfected HEK293T cells

doi: 10.1016/j.xpro.2026.104938

Figure Lengend Snippet:

Article Snippet: Human embryonic kidney 293T (HEK 293T) cells , ATCC , CRL-3216.

Techniques:

LFA‐1 engineering enhances EV localization to ECs. (A) Schematic illustration of the generation of LFA‐1‐engineered EVs. HEK293T cells were transfected with plasmids encoding CD11a and CD18, or vector control plasmids. EV Con and EV LFA‑1 were subsequently isolated from conditioned media by ultracentrifugation. (B) Western blot analysis using 50 µg EV protein lysates, showing expression of CD11a, CD18, and EV markers. (C and D) WT mice ( n = 4 per group) were treated intratracheally with LPS (5 µg per mouse). After 24 h, mice received an intravenous injection of 200 µg PKH26‑labeled EV Con or EV LFA‑1 and were euthanized 24 h later. Lung sections were stained with antibodies against CD68 (C) or CD31 (D). Nuclei were counterstained with DAPI. Scale bar = 50 µm. All in vitro experiments were conducted in three independent biological replicates.

Journal: Advanced Science

Article Title: LFA‐1‐Engineered Extracellular Vesicles Deliver CD59 to Protect Endothelial Integrity in Acute Lung Injury

doi: 10.1002/advs.78673

Figure Lengend Snippet: LFA‐1 engineering enhances EV localization to ECs. (A) Schematic illustration of the generation of LFA‐1‐engineered EVs. HEK293T cells were transfected with plasmids encoding CD11a and CD18, or vector control plasmids. EV Con and EV LFA‑1 were subsequently isolated from conditioned media by ultracentrifugation. (B) Western blot analysis using 50 µg EV protein lysates, showing expression of CD11a, CD18, and EV markers. (C and D) WT mice ( n = 4 per group) were treated intratracheally with LPS (5 µg per mouse). After 24 h, mice received an intravenous injection of 200 µg PKH26‑labeled EV Con or EV LFA‑1 and were euthanized 24 h later. Lung sections were stained with antibodies against CD68 (C) or CD31 (D). Nuclei were counterstained with DAPI. Scale bar = 50 µm. All in vitro experiments were conducted in three independent biological replicates.

Article Snippet: Human embryonic kidney cells (HEK293T) were obtained from American Type Culture Collection and maintained in DMEM with 10% FBS.

Techniques: Transfection, Plasmid Preparation, Control, Isolation, Ultracentrifugation, Western Blot, Analysis, Expressing, Injection, Staining, In Vitro

Engineered EV LFA−1 enriched with CD59 improves survival following K. p infection. (A) Schematic illustration of the generation of EV LFA−1 ‐CD59. (B) Western blot analysis using 50 µg EV or corresponding cell lysates following transfection, showing expression of CD11a, CD18, CD59, SP‐1, and EV markers Flotillin‐1 and CD9. (C) Representative TEM images of EV LFA−1 and EV LFA−1 ‐CD59 are shown. EVs labeled with anti‑CD59 immunogold staining were visualized by transmission electron microscopy. (D) The size distribution of EV LFA−1 and EV LFA−1 ‐CD59 was determined by NTA. All in vitro experiments were conducted in three independent biological replicates. (E and F) Primary lung ECs isolated from Cd59 − / − mice ( n = 4) were incubated with EV‐CD59 or EV LFA−1 ‐CD59 (50 µg/mL) for 2 h in the presence of heat‐inactivated normal human serum (HIHS). Representative CD59 immunofluorescence images showing cell‐associated CD59 (E). Quantification of CD59 fluorescence intensity using ImageJ (F). Nuclei were counterstained with DAPI. Scale bar = 50 µm. ** , p < 0.01.

Journal: Advanced Science

Article Title: LFA‐1‐Engineered Extracellular Vesicles Deliver CD59 to Protect Endothelial Integrity in Acute Lung Injury

doi: 10.1002/advs.78673

Figure Lengend Snippet: Engineered EV LFA−1 enriched with CD59 improves survival following K. p infection. (A) Schematic illustration of the generation of EV LFA−1 ‐CD59. (B) Western blot analysis using 50 µg EV or corresponding cell lysates following transfection, showing expression of CD11a, CD18, CD59, SP‐1, and EV markers Flotillin‐1 and CD9. (C) Representative TEM images of EV LFA−1 and EV LFA−1 ‐CD59 are shown. EVs labeled with anti‑CD59 immunogold staining were visualized by transmission electron microscopy. (D) The size distribution of EV LFA−1 and EV LFA−1 ‐CD59 was determined by NTA. All in vitro experiments were conducted in three independent biological replicates. (E and F) Primary lung ECs isolated from Cd59 − / − mice ( n = 4) were incubated with EV‐CD59 or EV LFA−1 ‐CD59 (50 µg/mL) for 2 h in the presence of heat‐inactivated normal human serum (HIHS). Representative CD59 immunofluorescence images showing cell‐associated CD59 (E). Quantification of CD59 fluorescence intensity using ImageJ (F). Nuclei were counterstained with DAPI. Scale bar = 50 µm. ** , p < 0.01.

Article Snippet: Human embryonic kidney cells (HEK293T) were obtained from American Type Culture Collection and maintained in DMEM with 10% FBS.

Techniques: Infection, Western Blot, Analysis, Transfection, Expressing, Labeling, Staining, Transmission Assay, Electron Microscopy, In Vitro, Isolation, Incubation, Immunofluorescence, Fluorescence

A) Schematic of the CRISPR screen workflow. B-C) Volcano plots of (B) the kinome screen results showing the log 2 FC vs −log 10 p-adjusted value (FDR<0.05) enrichment score per gene or (C) the genome-wide screen results showing the log 2 FC vs −log 10 p-value (p<0.08) enrichment score per gene that increased MeCP2 (green) or decreased MeCP2 (red) expression. D-E) Validation of top screen hits on endogenous MeCP2 levels relative to loading control (GAPDH) in HEK293T cells using independent sgRNAs or dual guide RNA vectors (dgRNAs). Combined bar plot showing target gene knockout (KO) efficiency (left) and corresponding changes to MeCP2 levels (right) as measured by western blot quantification compared to respective non-targeting (NT) control samples, stabilizers (red) and destabilizers (green). Data presented as mean ± SEM, **p<0.005, ***p<0.0005, ****p<0.0001 using a one-way ANOVA with post-hoc Dunnett’s multiple comparisons between gene-targeting sgRNAs or dgRNAs to respective NT samples. F-I) Quantification of endogenous MeCP2 levels relative to loading controls (GAPDH or VCL) in HEK293T cells after 72hr incubation with (F) BRD4 inhibitor JQ1 at 10uM, (G) CDK9 inhibitor LDC000067 at 10uM, (H) MTOR inhibitor Rapamycin at 1 uM, or (I) agonist of AMPK pathway Metformin at 0.5uM. Data presented as mean ± SEM, p-values determined using a Student’s t-test.

Journal: bioRxiv

Article Title: Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2 -related disorders

doi: 10.64898/2026.11.05.764603

Figure Lengend Snippet: A) Schematic of the CRISPR screen workflow. B-C) Volcano plots of (B) the kinome screen results showing the log 2 FC vs −log 10 p-adjusted value (FDR<0.05) enrichment score per gene or (C) the genome-wide screen results showing the log 2 FC vs −log 10 p-value (p<0.08) enrichment score per gene that increased MeCP2 (green) or decreased MeCP2 (red) expression. D-E) Validation of top screen hits on endogenous MeCP2 levels relative to loading control (GAPDH) in HEK293T cells using independent sgRNAs or dual guide RNA vectors (dgRNAs). Combined bar plot showing target gene knockout (KO) efficiency (left) and corresponding changes to MeCP2 levels (right) as measured by western blot quantification compared to respective non-targeting (NT) control samples, stabilizers (red) and destabilizers (green). Data presented as mean ± SEM, **p<0.005, ***p<0.0005, ****p<0.0001 using a one-way ANOVA with post-hoc Dunnett’s multiple comparisons between gene-targeting sgRNAs or dgRNAs to respective NT samples. F-I) Quantification of endogenous MeCP2 levels relative to loading controls (GAPDH or VCL) in HEK293T cells after 72hr incubation with (F) BRD4 inhibitor JQ1 at 10uM, (G) CDK9 inhibitor LDC000067 at 10uM, (H) MTOR inhibitor Rapamycin at 1 uM, or (I) agonist of AMPK pathway Metformin at 0.5uM. Data presented as mean ± SEM, p-values determined using a Student’s t-test.

Article Snippet: Human embryonic kidney cell T (HEK293T) were obtained from American Type Culture Collection (ATCC CRL-3216) and cultured according to manufacturer’s guidelines.

Techniques: CRISPR, Genome Wide, Expressing, Biomarker Discovery, Control, Gene Knockout, Western Blot, Gene Targeting, Incubation, FACS, Significance Assay

A) Prioritization of screen hits filtered by overlapping kinome-genome, human and mouse brain expression, MeCP2 PPIs , , druggability, and disease association (OMIM#). B) Venn diagram of overlapping clinical phenotypes of Rett syndrome (RTT), Okur Chung Neurodevelopmental Syndrome (OCNDS), and MECP2 duplication syndrome (MDS). C) Western blot and quantification of CSNK2A1 and MeCP2 total protein levels relative to loading control (VCL) in HEK293T-Cas9 cells infected with either dgCK2A1 or dgNT KO. D) Western blot and quantification of CSNK2A1 and MeCP2 levels relative to loading control (VCL) from HEK-293Ts overexpressing either YFP or CSNK2A1. Data presented as mean ± SEM, p-values calculated using a student’s t-test for C-D. E) IP western blot for FLAG or IgG in CSNK2A1 KO or WT (NT) HEK293Ts overexpressing Flag-MeCP2, probing for FLAG and CSNK2A1 in input and IP samples. F) IP western blot of endogenous MeCP2 or IgG control from mouse brain regions: cortex (CTX), hippocampus (HIP), or cerebellum (CB) in WT or Mecp2 -/y (MeCP2 null) mice. G) IP of MeCP2 at embryonic (E18) and post-natal timepoints (P5, P7, P28, and P63) and quantification of MeCP2-CSNK2A1 interaction over development (representative western blot from replicate 1). H) Schematic of intracerebroventricular (ICV) injection protocol using an AAV8 miR30-YFP 4-shRNA virus targeting Csnk2a1 or NT into P0 WT pups. I) 20X immunofluorescent (IF) image of the viral spread post-injection of an AAV-YFP-shNT injection at 4 weeks and colocalization with MeCP2 (gray) and neuron marker NeuN (magenta). J) Western blot and quantification of combined cortical/hippocampal protein samples at 8 weeks post-injection measuring levels of (K) CSNK2A1 and (L) MeCP2 relative to loading control (GAPDH). Data presented as mean ± SEM, p-values calculated using a student’s t-test between shNT and shCSNK2A1 samples.

Journal: bioRxiv

Article Title: Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2 -related disorders

doi: 10.64898/2026.11.05.764603

Figure Lengend Snippet: A) Prioritization of screen hits filtered by overlapping kinome-genome, human and mouse brain expression, MeCP2 PPIs , , druggability, and disease association (OMIM#). B) Venn diagram of overlapping clinical phenotypes of Rett syndrome (RTT), Okur Chung Neurodevelopmental Syndrome (OCNDS), and MECP2 duplication syndrome (MDS). C) Western blot and quantification of CSNK2A1 and MeCP2 total protein levels relative to loading control (VCL) in HEK293T-Cas9 cells infected with either dgCK2A1 or dgNT KO. D) Western blot and quantification of CSNK2A1 and MeCP2 levels relative to loading control (VCL) from HEK-293Ts overexpressing either YFP or CSNK2A1. Data presented as mean ± SEM, p-values calculated using a student’s t-test for C-D. E) IP western blot for FLAG or IgG in CSNK2A1 KO or WT (NT) HEK293Ts overexpressing Flag-MeCP2, probing for FLAG and CSNK2A1 in input and IP samples. F) IP western blot of endogenous MeCP2 or IgG control from mouse brain regions: cortex (CTX), hippocampus (HIP), or cerebellum (CB) in WT or Mecp2 -/y (MeCP2 null) mice. G) IP of MeCP2 at embryonic (E18) and post-natal timepoints (P5, P7, P28, and P63) and quantification of MeCP2-CSNK2A1 interaction over development (representative western blot from replicate 1). H) Schematic of intracerebroventricular (ICV) injection protocol using an AAV8 miR30-YFP 4-shRNA virus targeting Csnk2a1 or NT into P0 WT pups. I) 20X immunofluorescent (IF) image of the viral spread post-injection of an AAV-YFP-shNT injection at 4 weeks and colocalization with MeCP2 (gray) and neuron marker NeuN (magenta). J) Western blot and quantification of combined cortical/hippocampal protein samples at 8 weeks post-injection measuring levels of (K) CSNK2A1 and (L) MeCP2 relative to loading control (GAPDH). Data presented as mean ± SEM, p-values calculated using a student’s t-test between shNT and shCSNK2A1 samples.

Article Snippet: Human embryonic kidney cell T (HEK293T) were obtained from American Type Culture Collection (ATCC CRL-3216) and cultured according to manufacturer’s guidelines.

Techniques: Expressing, Western Blot, Control, Infection, Injection, shRNA, Virus, Marker

A-B) qRT-PCR of (A) CSNK2A1 and (B) MECP2 relative to ACTIN (housekeeping gene) in HEK293T-Cas9 cells infected with either dgCK2A1 (KO) or dgNT (control). C-D) Replicates (2 and 3) of IP for MeCP2 at embryonic (E18) and post-natal timepoints (P5, P7, P28, and P63) blotting for (C) CSNK2A1 or (D) MeCP2. (E-G) Dual in situ probes for Mecp2 and Csnk2a1 and stained with DAPI in a representative adult sagittal brain section at 10X (E) or 40X oil (F-G). OB= olfactory bulb, CTX= cortex, STR= striatum, HIP= hippocampus, CB= Cerebellum. Cornu Ammonis (CA) 1-3 and the dentate gyrus (DG) are subregions of the hippocampus. Scale bar= 1mm (E), 500um (F-G). H-I) qRT-PCR from AAV- shCsnk2a1 or shNT P0 mouse ICV injections quantifying (H) Csnk2a1 and (I) Mecp2 relative to Actin . Data presented as mean ± SEM, p-values using a Student’s t-test.

Journal: bioRxiv

Article Title: Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2 -related disorders

doi: 10.64898/2026.11.05.764603

Figure Lengend Snippet: A-B) qRT-PCR of (A) CSNK2A1 and (B) MECP2 relative to ACTIN (housekeeping gene) in HEK293T-Cas9 cells infected with either dgCK2A1 (KO) or dgNT (control). C-D) Replicates (2 and 3) of IP for MeCP2 at embryonic (E18) and post-natal timepoints (P5, P7, P28, and P63) blotting for (C) CSNK2A1 or (D) MeCP2. (E-G) Dual in situ probes for Mecp2 and Csnk2a1 and stained with DAPI in a representative adult sagittal brain section at 10X (E) or 40X oil (F-G). OB= olfactory bulb, CTX= cortex, STR= striatum, HIP= hippocampus, CB= Cerebellum. Cornu Ammonis (CA) 1-3 and the dentate gyrus (DG) are subregions of the hippocampus. Scale bar= 1mm (E), 500um (F-G). H-I) qRT-PCR from AAV- shCsnk2a1 or shNT P0 mouse ICV injections quantifying (H) Csnk2a1 and (I) Mecp2 relative to Actin . Data presented as mean ± SEM, p-values using a Student’s t-test.

Article Snippet: Human embryonic kidney cell T (HEK293T) were obtained from American Type Culture Collection (ATCC CRL-3216) and cultured according to manufacturer’s guidelines.

Techniques: Quantitative RT-PCR, Infection, Control, In Situ, Staining, Olfactory

A) Western blot and quantification of MeCP2 protein levels relative to loading control (GAPDH) in HEK293T cells incubated with CSNK2A1 inhibitor TBB or DMSO vehicle control for 72hrs at 1uM or 10uM. B) Structure of CDD-2021 compound and (C) western blot and quantification of MeCP2 protein levels (left) relative to loading control (VCL) or MECP2 RNA levels relative to ACTIN (housekeeping gene) via qRT-PCR (right) in HEK293T cells incubated with CDD- 2021 at nM doses for 72hrs. Data presented as mean ± SEM, p-values determined using a one-way ANOVA with post-hoc Dunnett’s multiple comparisons. D) Schematic of experimental design. Western blots and quantification of MeCP2 stability relative to loading control (GAPDH) using the DOX-inducible experimental design to overexpress MeCP2-e2 in the presence of TBB (10uM), CDD2021 (10uM), or DMSO (control). Data presented as mean ± SEM, p-values determined using a two-way ANOVA with Tukey’s post-hoc multiple comparisons **P<0.005. E) Timeline of experimental design. Western blots and quantification of endogenous levels of MeCP2 relative to loading control (GAPDH) following treatment with DMSO or CDD-2021 (250nM) for 72hrs followed by incubation with either MLN-4924 (0.3uM, Nedd8-activating enzyme inhibitor), MG-132 (10uM, proteasome inhibitor), or DMSO (vehicle) 8hrs prior to harvest. NEDD8 blot shows MLN-4924 effectively inhibits neddylation. Data presented as mean ± SEM, p-values determined using a one-way ANOVA with post-hoc Sidak’s multiple comparisons.

Journal: bioRxiv

Article Title: Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2 -related disorders

doi: 10.64898/2026.11.05.764603

Figure Lengend Snippet: A) Western blot and quantification of MeCP2 protein levels relative to loading control (GAPDH) in HEK293T cells incubated with CSNK2A1 inhibitor TBB or DMSO vehicle control for 72hrs at 1uM or 10uM. B) Structure of CDD-2021 compound and (C) western blot and quantification of MeCP2 protein levels (left) relative to loading control (VCL) or MECP2 RNA levels relative to ACTIN (housekeeping gene) via qRT-PCR (right) in HEK293T cells incubated with CDD- 2021 at nM doses for 72hrs. Data presented as mean ± SEM, p-values determined using a one-way ANOVA with post-hoc Dunnett’s multiple comparisons. D) Schematic of experimental design. Western blots and quantification of MeCP2 stability relative to loading control (GAPDH) using the DOX-inducible experimental design to overexpress MeCP2-e2 in the presence of TBB (10uM), CDD2021 (10uM), or DMSO (control). Data presented as mean ± SEM, p-values determined using a two-way ANOVA with Tukey’s post-hoc multiple comparisons **P<0.005. E) Timeline of experimental design. Western blots and quantification of endogenous levels of MeCP2 relative to loading control (GAPDH) following treatment with DMSO or CDD-2021 (250nM) for 72hrs followed by incubation with either MLN-4924 (0.3uM, Nedd8-activating enzyme inhibitor), MG-132 (10uM, proteasome inhibitor), or DMSO (vehicle) 8hrs prior to harvest. NEDD8 blot shows MLN-4924 effectively inhibits neddylation. Data presented as mean ± SEM, p-values determined using a one-way ANOVA with post-hoc Sidak’s multiple comparisons.

Article Snippet: Human embryonic kidney cell T (HEK293T) were obtained from American Type Culture Collection (ATCC CRL-3216) and cultured according to manufacturer’s guidelines.

Techniques: Western Blot, Control, Incubation, Quantitative RT-PCR, Stability

A) Western blot and quantification of MeCP2 levels relative to loading control (GAPDH) in HEK293T cells incubated with CX-4945 at low doses for 72hrs. Data presented as mean ± SEM, p-values determined using a one-way ANOVA with post-hoc Dunnett’s multiple comparisons. B-D) Quantification of ubiquitination assay performed in HEK293T cells. Briefly, HA-Ubiquitin and FLAG-MECP2 were transfected into cells +/−CDD2021 (1uM) for 48hr followed by an 8hr incubation with (B) DMSO (no inhibitor), (C) proteasome inhibitor (MG-132, 10uM), or (D) lysosome inhibitor (CQ, 40um) before harvest. IP of FLAG in each sample was followed by western blot and quantification of HA (Ubiquitinated MeCP2)/FLAG (total MeCP2). Data presented as mean ± SEM, p-values determined using a Student’s t-test.

Journal: bioRxiv

Article Title: Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2 -related disorders

doi: 10.64898/2026.11.05.764603

Figure Lengend Snippet: A) Western blot and quantification of MeCP2 levels relative to loading control (GAPDH) in HEK293T cells incubated with CX-4945 at low doses for 72hrs. Data presented as mean ± SEM, p-values determined using a one-way ANOVA with post-hoc Dunnett’s multiple comparisons. B-D) Quantification of ubiquitination assay performed in HEK293T cells. Briefly, HA-Ubiquitin and FLAG-MECP2 were transfected into cells +/−CDD2021 (1uM) for 48hr followed by an 8hr incubation with (B) DMSO (no inhibitor), (C) proteasome inhibitor (MG-132, 10uM), or (D) lysosome inhibitor (CQ, 40um) before harvest. IP of FLAG in each sample was followed by western blot and quantification of HA (Ubiquitinated MeCP2)/FLAG (total MeCP2). Data presented as mean ± SEM, p-values determined using a Student’s t-test.

Article Snippet: Human embryonic kidney cell T (HEK293T) were obtained from American Type Culture Collection (ATCC CRL-3216) and cultured according to manufacturer’s guidelines.

Techniques: Western Blot, Control, Incubation, Ubiquitin Proteomics, Transfection

A) Schematic of the IP/MS experiment and coverage (red line) with location of phosphorylated serine residues in distinct protein domains of MeCP2 (NTD= N-terminal domain, MBD= methyl CpG binding domain, ID= intervening domain, TRD= transcriptional repressor domain, CTD= C-terminal domain). B) Graph showing normalized quantification of phosphorylated peptides over total peptides detected in sgNT and sgCSNK2A1 samples (N=2/condition, no statistical comparisons). C-D) Schematic of pInducer DOX-inducible experiment with Flag-MECP2 (WT) vs Flag-MECP2 serine to alanine mutations (S80A, S229A, or S326A) with western blots and quantification of MeCP2 relative to loading control (GAPDH) across each timepoint normalized to 0hr (continuous DOX) timepoint. Data presented as mean ± SEM, p-values determined using a two-way ANOVA with Tukey’s post-hoc multiple comparisons.

Journal: bioRxiv

Article Title: Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2 -related disorders

doi: 10.64898/2026.11.05.764603

Figure Lengend Snippet: A) Schematic of the IP/MS experiment and coverage (red line) with location of phosphorylated serine residues in distinct protein domains of MeCP2 (NTD= N-terminal domain, MBD= methyl CpG binding domain, ID= intervening domain, TRD= transcriptional repressor domain, CTD= C-terminal domain). B) Graph showing normalized quantification of phosphorylated peptides over total peptides detected in sgNT and sgCSNK2A1 samples (N=2/condition, no statistical comparisons). C-D) Schematic of pInducer DOX-inducible experiment with Flag-MECP2 (WT) vs Flag-MECP2 serine to alanine mutations (S80A, S229A, or S326A) with western blots and quantification of MeCP2 relative to loading control (GAPDH) across each timepoint normalized to 0hr (continuous DOX) timepoint. Data presented as mean ± SEM, p-values determined using a two-way ANOVA with Tukey’s post-hoc multiple comparisons.

Article Snippet: Human embryonic kidney cell T (HEK293T) were obtained from American Type Culture Collection (ATCC CRL-3216) and cultured according to manufacturer’s guidelines.

Techniques: Protein-Protein interactions, Binding Assay, Western Blot, Control, Liquid Chromatography with Mass Spectroscopy, Tandem Mass Spectroscopy